150 related articles for article (PubMed ID: 32499195)
1. [Participant-funded clinical trials on rare diseases].
Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 32499195
[TBL] [Abstract][Full Text] [Related]
2. Participant-funded clinical trials on rare diseases.
Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 34092344
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
4. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
5. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
6. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
Picavet E; Cassiman D; Pinxten W; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
[TBL] [Abstract][Full Text] [Related]
7. Financing drug discovery for orphan diseases.
Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
[TBL] [Abstract][Full Text] [Related]
8. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
9. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
10. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
Largent EA; Pearson SD
Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
[No Abstract] [Full Text] [Related]
11. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
Copley-Merriman K
Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
[No Abstract] [Full Text] [Related]
12. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
13. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
14. A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.
Masters A; Nutt D
J Med Ethics; 2017 Nov; 43(11):730-736. PubMed ID: 28588147
[TBL] [Abstract][Full Text] [Related]
15. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
16. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
17. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Kumar Kakkar A; Dahiya N
Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
[TBL] [Abstract][Full Text] [Related]
18. We need a "made in Canada" orphan drug framework.
McMillan HJ; Campbell C
CMAJ; 2017 Oct; 189(41):E1274-E1275. PubMed ID: 29038319
[No Abstract] [Full Text] [Related]
19. Ethical dilemmas about orphan drugs for orphan diseases.
Isaacs D
J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
[No Abstract] [Full Text] [Related]
20. New Therapeutic Uses for Existing Drugs.
Austin BA; Gadhia AD
Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
